Rationing new medicines not most cost-effective | KPMG | UK
Share with your friends

Rationing a fifth of new medicines may not be the most cost-effective approach, says KPMG's Chief Medical Advisor

Rationing new medicines not most cost-effective

Professor Hilary Thomas, KPMG UK’s Chief Medical Advisor, comments on today’s news that cost cutting will restrict access to medicines.


Also on KPMG.com

Professor Hilary Thomas, KPMG UK’s Chief Medical Advisor:

“When it comes to value for money, our NHS is world-class. However, it is important that the health benefits of many innovative new medicines continue to be available to our population.

“If a new drug reduces disease exacerbations and therefore reduces hospital admissions, then it’s likely to be cost effective. I believe we need a more sophisticated way of evaluating this effectiveness in the UK, with a focus on patient outcomes and value, rather than the blunt instrument of drug pricing.”


For media enquiries please contact:

Helen Jackson, corporate communications assistant manager

T: +44 (0)118 373 1479

M: +44 (0)790 111 5649

Email: Helen.Jackson@kpmg.co.uk

Follow us on twitter: @kpmguk

About KPMG

KPMG LLP, a UK limited liability partnership, operates from 22 offices across the UK with approximately 13,500 partners and staff. The UK firm recorded a revenue of £2.07 billion in the year ended 30 September 2016. KPMG is a global network of professional firms providing Audit, Tax, and Advisory services. It operates in 152 countries and has 189,000 professionals working in member firms around the world. The independent member firms of the KPMG network are affiliated with KPMG International Cooperative ("KPMG International"), a Swiss entity. Each KPMG firm is a legally distinct and separate entity and describes itself as such. 

Connect with us


Request for proposal